Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
3.350
-0.020 (-0.59%)
At close: Jun 5, 2026, 4:00 PM EDT
3.290
-0.060 (-1.79%)
After-hours: Jun 5, 2026, 5:54 PM EDT
Lisata Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Lisata Therapeutics stock have an average target of $4.00, which predicts a 19.40% increase from the current stock price of 3.35.
Price Target: $4.00 (+19.40%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Lisata Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Nov '25 | Jan '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 1 | 0 | 0 |
| Buy | 2 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | May 18, 2026 |
| Brookline Capital Markets | Brookline Capital Markets | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Jan 21, 2026 |
Financial Forecast
Revenue This Year
n/a
from 170.00K
Decreased by -100.00%
Revenue Next Year
n/a
EPS This Year
-1.09
from -1.91
EPS Next Year
-1.16
from -1.09
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | ||
| Avg | n/a | ||
| Low | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -100.0% | ||
| Avg | -100.0% | ||
| Low | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | -1.09 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |